Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
2.
Recenti Prog Med ; 110(5): 255-258, 2019 05.
Artículo en Italiano | MEDLINE | ID: mdl-31140459

RESUMEN

We report the case of a 67-year-old man, with a past medical history of radiotherapy for nasopharyngeal carcinoma, who presented with the classical features of a hyperthyroidism (H), due to Graves' disease, with a high TSH receptor antibodies (TRAb) titre. Thyrostatic therapy was started, with gradual improvement of the symptoms and of the thyroid function tests. Two years later, TRAb became negative and the therapy was stopped. In the following months a previously unknown anterior pituitary insufficiency became evident. Therapy with cortisone acetate, L-thyroxine and testosterone was started, resulting in prolonged normalization of the clinical picture. Six years later a short relapse of H was observed, simultaneously to a new increase of TRAb titre, requiring the transitory interruption of the L-thyroxine therapy. In a few months span H disappeared and central hypothyroidism manifested again, so that the patient is still taking replacement therapy. This case illustrates how H and hypopituitarism are not mutually exclusive diagnoses and how, even if rarely, central hypothyroidism and H could alternate in the clinical history of the same patient.


Asunto(s)
Hipertiroidismo/diagnóstico , Hipopituitarismo/diagnóstico , Inmunoglobulinas Estimulantes de la Tiroides/inmunología , Anciano , Cortisona/administración & dosificación , Enfermedad de Graves/diagnóstico , Humanos , Masculino , Testosterona/administración & dosificación , Tiroxina/administración & dosificación
3.
Recenti Prog Med ; 108(5): 239-241, 2017 May.
Artículo en Italiano | MEDLINE | ID: mdl-28643815

RESUMEN

We describe a case of greater saphenous vein thrombosis in a 50-year-old previously healthy man, occurred only 3 weeks after starting testosterone (T) replacement therapy (20 mg/day, gel) for hypergonadotropic hypogonadism. There were no clinical known risk factors for thrombosis. Laboratory assessment of thrombophilia, performed later, revealed only methylenetetrahydrofolate reductase (MTHFR) A1298C polymorphism. On the basis of other recently reported cases, we suppose a relationship between androgenic therapy and venous thrombosis. We suggest the same caution before starting T replacement therapy in male as in female administration of estrogens.


Asunto(s)
Terapia de Reemplazo de Hormonas/efectos adversos , Testosterona/efectos adversos , Trombosis de la Vena/etiología , Terapia de Reemplazo de Hormonas/métodos , Humanos , Hipogonadismo/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Vena Safena/patología , Testosterona/administración & dosificación , Trombosis de la Vena/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA